Topic
Biosimilars
856 published works
Biosimilars Law Bulletin
PTAB Reforms Shift the Battleground: Why Ex Parte Reexaminations Are Gaining Ground as IPRs Fade
By Jake Rosvold, Aydin H. Harston
In the evolving biosimilar landscape, patent challenges remain a critical strategy to clear the path for market entry. Recent reforms at the Patent Trial and Appeal Board (PTAB) under Director…
Biosimilars Law Bulletin
How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated January 22, 2026
By Alex Shaver, Aydin H. Harston
Many Prolia®/Xgeva® (denosumab) biosimilars approved in 2025 by FDA and EMA. FDA grants first interchangeable status for rapid acting insulin aspart, KristyTM. EMA sets record with 44 biosimilar authorizations in…
Big Molecule Watch
Year in Review: Top Legal Developments of 2025
By Tara Thigpen|Riley Wyberg|Sam Herron
This past year contained a number of significant developments in litigation involving biologics and biosimilars. The following is a recap of the top three legal developments that we covered on…
Spicy IP
Biosimilarity is not Infringement- Full Stop
Translation: Don’t think we are on the same side, we are different. On Monday, a DB of the DHC allowed Zydus to manufacture and market a biosimilar of the drug Nivolumab, marketed…
Big Molecule Watch
Year in Review: Big Deals of 2025
As we head into what is anticipated to be a strong year for biopharma dealmaking, we look back at some of the biggest deals in 2025 that focus on biologics…
Big Molecule Watch
Celltrion and Sandoz Launch Their Aflibercept Biosimilars in Europe
On November 27, 2025, Celltrion announced that Health Canada approved EYDENZELT® (aflibercept-boav), a biosimilar referencing Regeneron’s EYLEA® (aflibercept), in both vial and pre-filled syringe form, to treat all indications approved…
Big Molecule Watch
FDA Approves mAbxience and Amneal’s Denosumab Biosimilars
By Riley Wyberg
On December 22, 2025, the FDA approved mAbxience and Amneal’s Biologics Licensing Applications (BLAs) for BONCRESA (denosumab-mobz) and OZILTUS (denosumab-mobz), biosimilars referencing Amgen’s PROLIA® (denosumab) and XGEVA® (denosumab), respectively. Under…
Big Molecule Watch
Biocon and Regeneron Enter Global Settlement on Aflibercept Biosimilar
By Riley Wyberg
On December 13, 2025, Biocon Biologics Ltd. (“Biocon”) and Regeneron Pharmaceuticals, Inc. (“Regeneron”) entered into a license and settlement agreement to dismiss all pending claims in the parties’ disputes over…
Big Molecule Watch
FDA Approves New Dose for Celltrion’s OMLYCLO (omalizumab-igec)
On December 3, 2025, Celltrion announced that the FDA has approved a new dose of OMLYCLO (omalizumab-igec), the first and only biosimilar designated as interchangeable with Genentech and Novartis’s XOLAIR…
Big Molecule Watch
European Biosimilar Updates – Six Denosumab Launches and Positive Opinion for Samsung Bioepis’s BYOOVIZ
By Timothy Beavers|Darlene Staines
Just in December, six companies have announced the launch of their denosumab biosimilars in Europe: Sandoz, Samsung Bioepis, Fresenius Kabi, Zentiva, Biocon Biologics, and Accord. On December 1, 2025: Sandoz…